Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Current Deferred Revenue: 2024-2025

Historic Current Deferred Revenue for Fennec Pharmaceuticals (FENC) over the last 2 years, with Sep 2025 value amounting to $248,000.

  • Fennec Pharmaceuticals' Current Deferred Revenue changed negligibly% to $248,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $248,000, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $248,000 for FY2024, which is N/A change from last year.
  • According to the latest figures from Q3 2025, Fennec Pharmaceuticals' Current Deferred Revenue is $248,000, which was down 0.00% from $248,000 recorded in Q2 2025.
  • Fennec Pharmaceuticals' 5-year Current Deferred Revenue high stood at $252,000 for Q1 2024, and its period low was $248,000 during Q3 2024.
  • For the 2-year period, Fennec Pharmaceuticals' Current Deferred Revenue averaged around $249,143, with its median value being $248,000 (2025).
  • Data for Fennec Pharmaceuticals' Current Deferred Revenue shows a maximum YoY dropped of 1.59% (in 2025) over the last 5 years.
  • Over the past 2 years, Fennec Pharmaceuticals' Current Deferred Revenue (Quarterly) stood at $248,000 in 2024, then remained steady at $248,000 in 2025.
  • Its Current Deferred Revenue stands at $248,000 for Q3 2025, versus $248,000 for Q2 2025 and $248,000 for Q1 2025.